Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) Tobramycin Sulfate Injection received approval from the National Medical Products Administration for its supplemental drug application after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Thursday.
The evaluation tested the consistency of the drug's quality and efficacy.
The drug is used to treat infection-related conditions, such as sepsis, pulmonary infections, bone infections and burns.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments